<DOC>
	<DOCNO>NCT02229864</DOCNO>
	<brief_summary>The ABSORB III PK sub-study prospective , open-label , non-blinded study enrol approximately 12 subject 5 US site . ABSORB III PK sub-study part ABSORB III RCT ( NCT01751906 ) . The objective determine pharmacokinetics everolimus deliver Absorb BVS separate non-randomized cohort subject receive Absorb BVS maximum two de novo native coronary artery lesion implantation Absorb BVS . Note : The ABSORB III PK subject contribute determination ABSORB III RCT primary endpoint .</brief_summary>
	<brief_title>Pharmacokinetics Everolimus Absorb BVS Patients With Coronary Artery Lesions</brief_title>
	<detailed_description>To ensure PK measurement reflect everolimus exposure due Absorb BVS , PK sub-study allow non-target lesion treatment . Blood Sampling Timing : - Pre-Absorb BVS implantation : Baseline Baseline define prior implantation first Absorb BVS ; blood sample draw day index procedure either heparin lock , venous sheath , venipuncture . - Post-Absorb BVS implantation : 10 30 minute , 1 hr , 2 hr , 4 hr , 6 hr , 12 hr , 24 hr ( 1 day ) , 48 hr ( 2 day ) , 72 hr ( 3 day ) , 96 hr ( 4 day ) , 120 hr ( 5 day ) , 168 hr ( 7 day ) , 336 hr ( 14 day ) , 720 hr ( 30 day ) . - Post-implantation blood sample draw time interval state ; time post-implantation sample begin last Absorb BVS deploy , i.e . last Absorb BVS delivery catheter remove body . Pharmacokinetic ( PK ) parameter include time maximum concentration ( tmax ) ; maximum concentration ( Cmax ) ; AUC24h : Area blood analyte concentration vs. time curve time 0 24 hour post placement last Absorb BVS ; AUClast : Area blood analyte concentration vs. time curve time 0 last quantifiable concentration ; AUC 0-infinity : Area blood analyte concentration vs. time curve time zero extrapolate infinite time ; terminal elimination rate constant ( λz ) ; terminal elimination half-life ( t1/2term ) ; drug clearance ( CL ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Constriction , Pathologic</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>General 1 . 18 year age . 2 . Subject legally authorize representative must provide write Informed Consent prior study related procedure , per site requirement . 3 . Evidence myocardial . In absence noninvasive ischemia , FFR must do indicative ischemia . 4 . An acceptable candidate coronary artery bypass graft ( CABG ) surgery . 5 . Female subject childbearing potential plan pregnancy 1 year follow index procedure . 6 . Female subject breastfeeding time screen visit breastfeed 1 year follow index procedure . 7 . Subject agree participate investigational invasive clinical study period 1 year follow index procedure . Angiographic 1 . One two de novo target lesion : 1 . If two target lesion present , must present different epicardial vessel must satisfy angiographic eligibility criterion . 2 . The definition epicardial vessel mean left anterior descending ( LAD ) , leave coronary artery ( LCX ) , right coronary artery ( RCA ) branch . Thus , patient must lesion require treatment e.g . LAD diagonal branch . 2 . Target lesion ( ) must locate native coronary artery visually estimate quantitatively assess % diameter stenosis ( DS ) ≥ 50 % &lt; 100 % thrombolysis myocardial infarction ( TIMI ) flow ≥ 1 one following : stenosis ≥ 70 % , abnormal functional test ( e.g. , fractional flow reserve ( FFR ) , stress test ) , unstable angina postinfarct angina . 1 . Lesion ( ) must locate native coronary artery reference vessel diameter ( RVD ) visual estimation ≥ 2.50 mm ≤ 3.75 mm . 2 . Lesion ( ) must locate native coronary artery length visual estimation ≤ 24 mm . General 1 . Any surgery require general anesthesia discontinuation aspirin and/or Adenosine diphosphate receptor ( ADP ) antagonist plan within 12 month procedure . 2 . Subject know hypersensitivity contraindication device material degradants ( everolimus , poly ( Llactide ) , poly ( DLlactide ) , lactide , lactic acid ) cobalt , chromium , nickel , platinum , tungsten , acrylic fluoro polymer adequately premedicated . Subject know contrast sensitivity adequately premedicated . 3 . Subject know allergic reaction , hypersensitivity contraindication aspirin ; clopidogrel prasugrel ticagrelor ; heparin bivalirudin , therefore adequately treat study medication . 4 . Subject acute myocardial infarction ( AMI : STEMI NSTEMI ) within 72 hour index procedure creatine kinase ( CK ) creatine kinase myocardialband isoenzyme ( CKMB ) return within normal limit time index procedure ; subject stable angina silent ischemia CKMB great normal limit time index procedure . 5 . Subject currently experience clinical symptom consistent new onset AMI ( STEMI NSTEMI ) , nitrateunresponsive prolong chest pain ischemic ECG change . 6 . Subject cardiac arrhythmia identify time screen least one follow criterion meet : 1 . Subject require coumadin agent chronic oral anticoagulation 2 . Subject likely become hemodynamically unstable due arrhythmia 3 . Subject poor survival prognosis due arrhythmia 7 . Subject leave ventricular ejection fraction ( LVEF ) &lt; 30 % 8 . Subject undergone prior percutaneous coronary intervention ( PCI ) within target vessel ( ) last 12 month . 9 . Subject require future stag PCI either target nontarget vessel subject require future peripheral intervention &lt; 30 day index procedure . 10 . Subject receive solid organ transplant wait list solid organ transplant . 11 . At time screening , subject malignancy remission . 12 . Subject receive immunosuppressant therapy know immunosuppressive severe autoimmune disease require chronic immunosuppressive therapy ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , etc. ) . Note : corticosteroid include immunosuppressant therapy . 13 . Subject previously receive schedule receive radiotherapy coronary artery ( vascular brachytherapy ) , chest/mediastinum . 14 . Subject receive require chronic anticoagulation therapy ( e.g. , coumadin , dabigatran , apixaban , rivaroxaban agent reason ) . 15 . Subject platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 . 16 . Subject document suspected hepatic disorder define cirrhosis ChildPugh ≥ Class B . 17 . Subject renal insufficiency define estimate glomerular filtration rate ( GFR ) &lt; 30 ml/min/1.73m2 dialysis time screen . 18 . Subject high risk bleed reason ; history bleed diathesis coagulopathy ; significant gastrointestinal significant urinary bleed within past six month . 19 . Subject cerebrovascular accident transient ischemic neurological attack ( TIA ) within past six month , prior intracranial bleed , permanent neurologic defect , know intracranial pathology ( e.g. , aneurysm , arteriovenous malformation , etc. ) . 20 . Subject extensive peripheral vascular disease precludes safe 6 French sheath insertion . Note : femoral arterial disease exclude patient radial access may use . 21 . Subject life expectancy &lt; 5 year noncardiac cause cardiac cause . 22 . Subject opinion Investigator designee , unable comply requirement study protocol unsuitable study reason . 23 . Subject currently participate another clinical trial yet complete primary endpoint . 24 . Subject part vulnerable population Angiographic All exclusion criterion apply target lesion ( ) target vessel ( ) . 1 . Lesion prevents successful balloon predilatation 2 . Lesion locate leave main . 3 . Aortoostial RCA lesion . 4 . Lesion locate within 3 mm origin LAD LCX . 5 . Lesion involve bifurcation : 1. side branch ≥ 2 mm diameter , 2. side branch either ostial nonostial lesion diameter stenosis &gt; 50 % , 3. side branch require dilatation . 6 . Anatomy proximal within lesion may impair delivery Absorb BVS . 7 . Vessel contain thrombus indicate angiographic image intravascular ultrasound ( IVUS ) optical coherence tomography ( OCT ) . 8 . Lesion vessel involve myocardial bridge . 9 . Vessel previously treat stent time prior index procedure Absorb BVS would need cross stent reach target lesion . 10 . Vessel previously treat target lesion within 5 mm proximal distal previously treat lesion . 11 . Target lesion locate within arterial saphenous vein graft distal arterial saphenous vein graft .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Absorb™ BVS</keyword>
	<keyword>Angioplasty</keyword>
	<keyword>Bioabsorbable</keyword>
	<keyword>BVS</keyword>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Coronary Artery Endothelial Responsiveness</keyword>
	<keyword>Coronary artery restenosis</keyword>
	<keyword>Coronary artery stenosis</keyword>
	<keyword>Coronary scaffold</keyword>
	<keyword>Coronary Stent</keyword>
	<keyword>Drug elute stent</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Myocardial ischemia</keyword>
	<keyword>Stent thrombosis</keyword>
	<keyword>Stents</keyword>
</DOC>